Collegium Pharmaceutical (COLL) PT Lowered to $36 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts COLL Hot Sheet
Price: $23.00 -0.9%
Rating Summary:
10 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
10 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Piper Sandler analyst David Amsellem lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $36.00 (from $37.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Standard Chartered Plc. (STAN:LN) (SCBFF) PT Raised to GBP27.90 at Goldman Sachs
- JPMorgan Reiterates Overweight Rating on Standard Chartered Plc. (STAN:LN) (SCBFY)
- JPMorgan Downgrades Xylem (XYL) to Underweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
